Today: 30 April 2026
P&G stock in focus: Barclays lifts target ahead of Jan. 22 earnings, warns rally is a “flight to safety”
18 January 2026
2 mins read

P&G stock in focus: Barclays lifts target ahead of Jan. 22 earnings, warns rally is a “flight to safety”

New York, Jan 18, 2026, 11:38 AM EST — Market closed.

  • Procter & Gamble shares slipped 0.1% to close Friday at $144.53.
  • Barclays increased its price target to $155 but maintained an Equal Weight rating.
  • The U.S. markets will be closed Monday; P&G is set to release quarterly results and hold its earnings call on Jan. 22.

Procter & Gamble shares slipped 0.1% on Friday, finishing at $144.53. The stock wrapped up the long weekend stuck close to the mid-$140 range.

The broader market offered little momentum. On Friday, U.S. stocks closed nearly unchanged, with the three major indexes logging small weekly declines as earnings season got underway and investors braced for the upcoming market holiday, Reuters reported. “To finish the week around flat” while the S&P 500 hovers near 7,000 “is a win in most investors’ books,” said Anthony Saglimbene, chief market strategist at Ameriprise Financial. Reuters

P&G’s stock has been acting as a safe haven lately. Barclays analyst Lauren Lieberman bumped her price target to $155 from $151 but kept an Equal Weight rating, signaling she expects the shares to track their peers. She described the recent surge as “a flight to safety” and pointed to potential oil and currency challenges in 2026. (A price target is an analyst’s projection of where a stock might head over time.) TipRanks

P&G, known for Tide detergent and Pampers diapers, operates in the consumer staples sector — a market segment that typically holds steady when investors grow cautious. Its reputation for low volatility works both ways: it attracts steady investment but can fall behind when risk appetite returns.

P&G will hold its fiscal second-quarter earnings call on Jan. 22 at 8:30 a.m. ET, per the company’s investor relations calendar.

As the company nears its earnings report, traders are set to focus on pricing and volume updates, plus any insights into demand for everyday goods following the holiday shopping surge. Guidance will be scrutinized closely, particularly the commentary on “organic” growth — sales growth that excludes currency fluctuations and acquisitions.

The New York Stock Exchange calendar confirms markets will be closed Monday for Martin Luther King Jr. Day, tightening the trading week and limiting opportunities for investors to adjust their positions.

But that defensive bid could quickly unravel if the results disappoint. A weaker sales mix, unexpected margin pressure, or a cautious stance on costs might push P&G beyond its tight trading range—especially if investors conclude the “safety” trade has become too crowded.

Staples showed a split picture heading into the weekend: Clorox dropped 1.1% on Friday, while Colgate-Palmolive nudged higher. This divergence underscores the growing influence of company-specific factors as earnings season picks up.

Thursday brings the next major trigger. P&G is set to release earnings on Jan. 22 before markets open, per Nasdaq’s earnings calendar. Investors will be watching closely to see if the company can hold onto growth and margins amid a market favoring more stable stocks.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Netflix stock price steadies near $88 as Trump bond disclosure, Sony deal and Warner fight crowd the week
Previous Story

Netflix stock price steadies near $88 as Trump bond disclosure, Sony deal and Warner fight crowd the week

GE Aerospace stock price: GE shares head into earnings week after Friday lift
Next Story

GE Aerospace stock price: GE shares head into earnings week after Friday lift

Go toTop